Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 223

1.

Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia.

Claus R, Pfeifer D, Almstedt M, Zucknick M, Hackanson B, Plass C, Lübbert M.

Leuk Res. 2013 Feb;37(2):190-6. doi: 10.1016/j.leukres.2012.10.015. Epub 2012 Nov 15.

PMID:
23158571
2.

Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.

Fabiani E, Leone G, Giachelia M, D'alo' F, Greco M, Criscuolo M, Guidi F, Rutella S, Hohaus S, Voso MT.

Leuk Lymphoma. 2010 Dec;51(12):2275-84. doi: 10.3109/10428194.2010.528093. Epub 2010 Nov 15.

PMID:
21077739
3.

The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.

Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, Karbach J, Pfeifer D, Jäger E, Lübbert M.

Leuk Res. 2010 Jul;34(7):899-905. doi: 10.1016/j.leukres.2010.02.004. Epub 2010 Apr 10.

PMID:
20381863
4.

Genomic impact of transient low-dose decitabine treatment on primary AML cells.

Klco JM, Spencer DH, Lamprecht TL, Sarkaria SM, Wylie T, Magrini V, Hundal J, Walker J, Varghese N, Erdmann-Gilmore P, Lichti CF, Meyer MR, Townsend RR, Wilson RK, Mardis ER, Ley TJ.

Blood. 2013 Feb 28;121(9):1633-43. doi: 10.1182/blood-2012-09-459313. Epub 2013 Jan 7.

5.

Digging deep into "dirty" drugs - modulation of the methylation machinery.

Pleyer L, Greil R.

Drug Metab Rev. 2015 May;47(2):252-79. doi: 10.3109/03602532.2014.995379. Epub 2015 Jan 8. Review.

6.

DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.

Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V, Luna R, Rashid A, Shen L, Estecio MR, Kantarjian HM, Garcia-Manero G, Issa JP.

Cancer Res. 2006 May 15;66(10):5495-503.

7.

Differential TERT promoter methylation and response to 5-aza-2'-deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death.

Pettigrew KA, Armstrong RN, Colyer HA, Zhang SD, Rea IM, Jones RE, Baird DM, Mills KI.

Genes Chromosomes Cancer. 2012 Aug;51(8):768-80. doi: 10.1002/gcc.21962. Epub 2012 Apr 19.

PMID:
22517724
8.

Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.

Kopp LM, Ray A, Denman CJ, Senyukov VS, Somanchi SS, Zhu S, Lee DA.

Mol Immunol. 2013 Jul;54(3-4):296-301. doi: 10.1016/j.molimm.2012.12.012. Epub 2013 Jan 16.

PMID:
23328088
9.
10.

Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.

Estey EH.

Leukemia. 2013 Sep;27(9):1803-12. doi: 10.1038/leu.2013.173. Epub 2013 Jun 12. Review.

PMID:
23757301
11.

Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.

Yan P, Frankhouser D, Murphy M, Tam HH, Rodriguez B, Curfman J, Trimarchi M, Geyer S, Wu YZ, Whitman SP, Metzeler K, Walker A, Klisovic R, Jacob S, Grever MR, Byrd JC, Bloomfield CD, Garzon R, Blum W, Caligiuri MA, Bundschuh R, Marcucci G.

Blood. 2012 Sep 20;120(12):2466-74. Epub 2012 Jul 11.

12.

Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma.

Rubinstein JC, Tran N, Ma S, Halaban R, Krauthammer M.

BMC Med Genomics. 2010 Feb 9;3:4. doi: 10.1186/1755-8794-3-4.

13.

Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia.

Yun H, Damm F, Yap D, Schwarzer A, Chaturvedi A, Jyotsana N, Lübbert M, Bullinger L, Döhner K, Geffers R, Aparicio S, Humphries RK, Ganser A, Heuser M.

Haematologica. 2014 Sep;99(9):1456-64. doi: 10.3324/haematol.2013.101386. Epub 2014 Jun 3.

14.

[Epigenetic regulation of expression of retinoic acid receptor beta gene in leukemia cell].

Meng YS, Ma XX, Meng XQ, Wei R, Liu W, Ai GW, Zhang YX.

Zhonghua Yi Xue Za Zhi. 2007 Dec 25;87(48):3406-10. Chinese.

PMID:
18476539
15.

Effect of cytarabine and decitabine in combination in human leukemic cell lines.

Qin T, Youssef EM, Jelinek J, Chen R, Yang AS, Garcia-Manero G, Issa JP.

Clin Cancer Res. 2007 Jul 15;13(14):4225-32.

16.

Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.

Raneros AB, Puras AM, Rodriguez RM, Colado E, Bernal T, Anguita E, Mogorron AV, Gil AC, Vidal-Castiñeira JR, Márquez-Kisinousky L, Bulnes PD, Marin AM, Garay MCG, Suarez-Alvarez B, Lopez-Larrea C.

Oncotarget. 2017 May 9;8(19):31959-31976. doi: 10.18632/oncotarget.16657.

17.

The cancer‑testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo.

Zhou J, Li Y, Yao Y, Wang L, Gao L, Gao X, Luo X, Li J, Jiang M, Zhou M, Wang L, Yu L.

Mol Med Rep. 2013 Nov;8(5):1549-55. doi: 10.3892/mmr.2013.1659. Epub 2013 Aug 28.

PMID:
24002123
18.

The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.

Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, Plass C, Niemeyer CM, Lübbert M.

Leukemia. 2009 Jun;23(6):1019-28. doi: 10.1038/leu.2008.397. Epub 2009 Feb 5.

PMID:
19194470
19.

The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia.

Agrawal S, Hofmann WK, Tidow N, Ehrich M, van den Boom D, Koschmieder S, Berdel WE, Serve H, Müller-Tidow C.

Blood. 2007 May 1;109(9):3895-905. Epub 2007 Jan 18.

20.

Activation of HLA-G expression by 5-aza-2 - deoxycytidine in malignant hematopoetic cells isolated from leukemia patients.

Polakova K, Bandzuchova E, Sabty FA, Mistrik M, Demitrovicova L, Russ G.

Neoplasma. 2009;56(6):514-20.

PMID:
19728760

Supplemental Content

Support Center